Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Coagulation factor IXa recombinant** is a recombinant form of activated human coagulation factor IX, a serine protease in the intrinsic coagulation cascade. In physiology, factor IXa complexes with activated factor VIII on phospholipid surfaces in the presence of calcium to form the intrinsic tenase complex, which activates factor X to factor Xa and thereby amplifies thrombin generation and fibrin clot formation. As a therapeutic concept, recombinant factor IX products are well established for hemophilia B, but marketed products are generally recombinant factor IX zymogen rather than activated recombinant factor IXa specifically; therefore the query most likely refers to an activated mechanistic form or a nonstandard/experimental designation rather than a clearly marketed standalone drug product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on coagulation factor IXa recombinant.